secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2026-08-06T11:30:20+00:00
Accession:  0001171843-26-005292
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics Q2 net loss $25.2M; tovecimig ORR improves to 18.0% with p=0.0228
--------------------------------------------------------------------------------

- Net loss of $25.2M ($0.13/sh) vs $19.9M ($0.14/sh) in Q2 2025; R&D spend rose 19% to $19.6M.
- Cash and marketable securities $180M as of June 30, 2026; runway into 2028.
- Tovecimig Phase 2/3 ORR improved to 18.0% (20/111) with p=0.0228 vs paclitaxel 5.3%.
- FDA feedback on tovecimig data expected Q3 2026; BLA submission planned later this year.
- CTX-8371 cohort expansions enrolling; CTX-10726 Phase 1 dosed; CTX-471 Phase 2 starts Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/0001171843-26-005292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/f8k_080526.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-005292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer